Proportion of patients eligible for adjuvant immunotherapy in nonmetastatic clear‐cell renal cell carcinoma treated with radical or partial nephrectomy

Editorial Comment to Proportion of patients eligible for adjuvant immunotherapy in nonmetastatic clear‐cell renal‐cell carcinoma treated with radical or partial nephrectomy

“…As a result, in both unadjusted DFS and overall survival (OS), patients with ≤pT3a were significantly better than those with ≥pT3b. In addition, multivariate analysis revealed that ≥T3b in pathological T stage was a significant risk factor for poor DFS and OS 2 . Increasing evidence suggests that response to immunotherapy in RCC is independent of the CD8 + T cell infiltration, or PD‐L1 expression, 3 therefore, careful patient selection using clinical variables including pathological stage as shown in this article should be performed for determining the treatment.…”